Tag: COVID-19

  • CureVac is an Underappreciated Opportunity, Says UBS

    CureVac is an Underappreciated Opportunity, Says UBS

    Investors may want to keep an eye on CureVac (CVAC). After pulling back from about $12.50 to $10.50, CVAC could see higher highs.  In fact, according to a UBS analyst, the stock is ready to compete in the big leagues. “UBS analyst Eliana Merle upgraded the shares to Buy from Neutral and raised her 12-month…

  • This is Why Pfizer Just Popped, As We Expected

    This is Why Pfizer Just Popped, As We Expected

    Pfizer is pushing to higher highs. In fact, as we noted on November 2, “After finding support around $41, the vaccine stock bolted to nearly $46, and could test $47, even $50, near-term.  All after the company raised its full-year sales forecast to $36 billion, as it signed deals for booster doses.  The stock could…

  • Three of the Best Ways to Hedge for Volatility

    Three of the Best Ways to Hedge for Volatility

    Volatility could easily rocket higher with a great deal of uncertainty. “We expect volatility to increase over the next month driven by a seasonal pickup in investor uncertainty, continued virus uncertainty, and significant monetary and fiscal policy catalysts,” wrote John Marshall, head of derivatives research for Goldman Sachs, as quoted by CNBC. In addition, the…

  • Why Cruise Stocks Could Sink Even More

    Why Cruise Stocks Could Sink Even More

    Cruise stocks are getting sunk. All thanks to the spread of the coronavirus all around the world. In the U.S. for example, according to CNBC, “Cases have rebounded in the U.S. this month with the delta variant spreading among the unvaccinated. The U.S. is averaging nearly 30,000 new cases a day in the last 7-days…

  • The 2021 Tokyo Olympics Could be Canceled

    The 2021 Tokyo Olympics Could be Canceled

    The Tokyo Olympics may not happen. Just weeks ahead of the games, Japan is seeing a significant number of new COVID-19 cases, leading to calls to cancel the Games.  Worse, hospitals in Osaka are at a breaking points, says The Sun, which added there’s a big shortage of ventilators and sedation drug, Propofol. “The Olympics…

  • Ocugen Could Easily Soar to Higher Highs

    Ocugen Could Easily Soar to Higher Highs

    Ocugen has been explosive. Since December 2020, the stock ran from a low of 29 cents to $13 good for a return of 4,383%.  However, even after the run, OCGN could see further upside. All after its development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase 3 study of…

  • Johnson & Johnson (JNJ) May Be Ready to Rebound

    Johnson & Johnson (JNJ) May Be Ready to Rebound

    Keep an eye on Johnson & Johnson (JNJ). After pulling back from a high of $173.65, it caught support at $161.99.  From here, the stock could again test prior highs if the US FDA grants emergency authorization for its vaccine. With a 66% effective rate in protecting against the virus, JNJ applied for emergency use.…

  • How to Trade the Wild Market Uncertainty

    How to Trade the Wild Market Uncertainty

    Uncertainty is driving markets nuts again. All on talk of impeachment, and ahead of Joe Biden’s inauguration. At the moment, House Democrats care calling on Vice President Mike Pence to invoke the 25th amendment and remove President Trump from office.  The House is also expected to vote on impeachment by Tuesday. Not helping, the Speaker of…

  • The Top 3 Vaccine Trades that Should be in All Portfolios

    The Top 3 Vaccine Trades that Should be in All Portfolios

    Moderna (MRNA) has been incredibly explosive for us. The first time we highlighted opportunity, the stock traded at $72 on Oct. 20.  At the moment, it’s up to $171.92 in pre-market, and we still believe it could rally to $200. For one, “This positive primary analysis confirms the ability of our vaccine to prevent COVID-19…

  • This is Why Moderna Could Run to $200, Near-Term

    This is Why Moderna Could Run to $200, Near-Term

    Vaccine news has created big opportunity. Look at BioNTech for example.  The stock exploded from $88.50 to $124.24 after it and Pifzer said its vaccine had a 95% effective rate with no safety concerns. “Efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%,”Pfizer…